Nyctea Technologies utilizes electronically activated biomolecule control to purify biopharmaceuticals without the need for elution buffers, enabling real-time monitoring and minimal waste. This technology significantly reduces production costs, making biopharmaceuticals more affordable and accessible.
Funding
$760K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional biopharmaceutical purification methods rely on elution buffers, which can be harsh on sensitive biomolecules, generate significant waste, and lack real-time monitoring capabilities, leading to increased production costs.
Solution
Nyctea Technologies offers a novel biopharmaceutical purification platform that utilizes electronically activated biomolecule control, eliminating the need for elution buffers. This gentle purification method minimizes waste and enables true real-time monitoring of the purification process. By reducing buffer consumption and enabling precise control, Nyctea's technology lowers production costs, making biopharmaceuticals more affordable and accessible. The platform is designed to handle a variety of next-generation biopharmaceuticals, including antibodies, oligonucleotides, viral vectors, LNPs, and enzymes.
Target Audience
The primary target audience includes biopharmaceutical manufacturers seeking to reduce production costs and improve the efficiency and gentleness of their purification processes.
Features
- Electrically activated biomolecule control for precise purification.
- Elution buffer-free process, ensuring gentle purification of sensitive biopharmaceuticals.
- Real-time monitoring of the purification process.
- Minimal waste and reduced buffer consumption.
- Suitable for antibodies, oligonucleotides, viral vectors, LNPs, and enzymes.